Related Experiment Video
Updated: Dec 24, 2025
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
71.0K
High-protein meals require 30% additional insulin to prevent delayed postprandial hyperglycaemia.
M A Paterson1,2, C E M Smart1,2, P Howley3
1Department of Paediatric Endocrinology and Diabetes, John Hunter Children's Hospital, Newcastle, Australia.
Summary
For individuals with type 1 diabetes on insulin pump therapy, a 30% increase in insulin dose for high-protein meals effectively prevents high blood sugar without raising hypoglycemia risk.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Diabetes Management
Background:
- Postprandial hyperglycemia is a common challenge for individuals with type 1 diabetes, particularly after high-protein meals.
- Insulin pump therapy requires precise insulin dosing to manage blood glucose levels effectively.
Purpose of the Study:
- To determine the optimal additional insulin dose needed to prevent postprandial hyperglycemia in type 1 diabetes patients consuming high-protein meals.
- To evaluate the safety and efficacy of different insulin dosing strategies using insulin pump therapy.
Main Methods:
- A randomized cross-over study involving 26 participants (aged 8-40) with type 1 diabetes.
- Participants consumed a standardized high-protein breakfast drink over five days.
- Different insulin doses (100%, 115%, 130%, 145%, 160% of standard) were administered via combination bolus, with continuous glucose monitoring used to assess postprandial glycemia.
Main Results:
- Standard insulin dosing (100%) led to postprandial hyperglycemia.
- Doses of 130% or higher significantly reduced postprandial glucose excursions compared to the standard dose.
- A 130% insulin dose effectively lowered glucose levels without increasing the risk of hypoglycemia, unlike higher doses (145% and 160%) which elevated hypoglycemia risk.
Conclusions:
- An additional 30% insulin dose, delivered via combination bolus, is effective in managing postprandial hyperglycemia from high-protein meals in type 1 diabetes.
- This adjusted dosing strategy improves glycemic control without a significant increase in hypoglycemia events.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
579
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
579
01:15Hypoglycemia and Glucagon
722
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
722
01:16Hormones Regulating Blood Glucose
6.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
485
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
485
01:27Insulin Formulations: Types and Delivery
553
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
553
01:06Oral Hypoglycemic Agents: Glinides
500
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
500